Differences among young adults, adults and elderly chronic myeloid leukemia patientsFabio Castagnetti, Mariella Girasoli, Gabriele Gugliotta et al.|Annals of Oncology|2014Cited by 99
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Michele Baccarani, Sara Galimberti et al.|Annals of Hematology|2017Cited by 38
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Danilo Perrotti, Rossana Trotta et al.|Blood Cancer Discovery|2020Cited by 34
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIBFrancesco Cavazzini, G Gozzini, Raffaele Porrini et al.|Institutional Research Information System University of Ferrara (University of Ferrara)|2010Cited by 1